Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL.
Janneke A EkenMarvyn T KoningKristyna KupcovaJulieta Haydee Sepúlveda YáñezRuben A L de GroenEdwin QuintenJurriaan JanssenCornelis A M van BergenJoost S P VermaatArjen H G ClevenMarcelo A NavarreteBauke YlstraDaphne de JongOndrej HavranekHassan JumaaJoan Hendrik VeelkenPublished in: The Journal of experimental medicine (2024)
Diffuse large B cell lymphoma of activated B cell type (ABC-DLBCL), a major cell-of-origin DLBCL subtype, is characterized by chronic active B cell receptor (BCR) signaling and NF-κB activation, which can be explained by activating mutations of the BCR signaling cascade in a minority of cases. We demonstrate that autonomous BCR signaling, akin to its essential pathogenetic role in chronic lymphocytic leukemia (CLL), can explain chronic active BCR signaling in ABC-DLBCL. 13 of 18 tested DLBCL-derived BCR, including 12 cases selected for expression of IgM, induced spontaneous calcium flux and increased phosphorylation of the BCR signaling cascade in murine triple knockout pre-B cells without antigenic stimulation or external BCR crosslinking. Autonomous BCR signaling was associated with IgM isotype, dependent on somatic BCR mutations and individual HCDR3 sequences, and largely restricted to non-GCB DLBCL. Autonomous BCR signaling represents a novel immunological oncogenic driver mechanism in DLBCL originating from individual BCR sequences and adds a new dimension to currently proposed genetics- and transcriptomics-based DLBCL classifications.
Keyphrases
- diffuse large b cell lymphoma
- acute lymphoblastic leukemia
- chronic myeloid leukemia
- tyrosine kinase
- epstein barr virus
- signaling pathway
- chronic lymphocytic leukemia
- single cell
- stem cells
- dna methylation
- mesenchymal stem cells
- gene expression
- drug induced
- immune response
- genome wide
- cell proliferation
- genetic diversity